Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 10/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713815 | 0.82 | PDE4A (0.57) | TPH1RECQLPDE4APDE4BPDE4C | |
| SCHEMBL7940449 | 0.80 | RECQL (0.55) | TPH1RECQLPDE4APDE4BPDE4C | |
| SCHEMBL309631 | 0.78 | TPH1 (0.51) | TPH1RECQLPDE4APDE4BPDE4C | |
| SCHEMBL307931 | 0.78 | TPH1 (0.49) | TPH1RECQLPDE4APDE4BPDE4C | |
| SCHEMBL308215 | 0.77 | TPH1 (0.49) | TPH1RECQLPDE4APDE4BPDE4C | |
| SCHEMBL7937862 | 0.77 | RECQL (0.52) | TPH1RECQLPDE4APDE4BPDE4C | |
| SCHEMBL23260728 | 0.76 | MEN1 (0.56) | TPH1MEN1KMT2A | |
| SCHEMBL13317191 | 0.76 | RECQL (0.61) | RECQLPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7422660 | 0.75 | PDE4B (0.49) | TPH1RECQLPDE4APDE4BPDE4C | |
| SCHEMBL7424560 | 0.75 | RECQL (0.49) | TPH1RECQLPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102186476-A | Tryptophan hydroxylase inhibitors and methods of their use | LEXICON PHARMACEUTICALS INC | 2011-09-14 | — | — | CN | disclosed |
| EP-2344160-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100087433-A1 | Methods of inhibiting tryptophan hydroxylase | LEXICON PHARMACEUTICALS, INC. | 2010-04-08 | — | — | US | disclosed |
| WO-2010039957-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087433-A1 | Methods of inhibiting tryptophan hydroxylase | TPH1, TPH2, HNMT | TPH1 1/4885RECQL 1002/4885PDE4A 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.